Can Humana’s 12% Star Rating Rally Hold Into Q4?

NEW YORK — On Thursday, October 9, Humana’s stock did something it had not done in over a year: it put up a 12% single-session gain, closing at $431.87 on volume of nearly five million shares — more than three times its daily average — after the Centers for Medicare & Medicaid Services handed the company a four-star rating on its primary Medicare Advantage contract for plan year 2027.

Why Medicare Star Ratings Move Billions in Revenue

The CMS Medicare Advantage Star Rating system is not a marketing badge — it determines whether insurers receive quality bonus payments that can meaningfully alter per-member economics. Plans rated four stars or higher receive higher benchmark payments from the federal government, which in turn fund richer benefits, lower premiums, or fatter margins depending on how a carrier chooses to allocate the windfall.

Humana’s prior fall from grace on this metric was steep. In 2026, only 20% of its Medicare Advantage members were in four-star-or-higher plans, leaving the company locked out of billions in potential bonus payments at exactly the moment it was trying to rebuild margins after a brutal 2024–2025 cost cycle. Thursday’s CMS release reversed that almost entirely, lifting coverage to 95% of members — a result that blew past J.P. Morgan’s pre-release estimate of 60% to 70%.

The sector reaction was stark. While Humana surged, CVS Health fell roughly 5% and ALHC dropped more than 20% as traders punished names whose ratings came in below expectations. This was not a rising-tide event. The market made a precise, discriminating judgment about which carriers won and which lost — and Humana won emphatically.

Data Visual

Humana Medicare Advantage Star Rating Coverage: 2026 vs. 2027

Shows the dramatic shift in the share of Humana’s Medicare Advantage members enrolled in four-star-or-higher plans, the threshold for CMS quality bonus payments.

Values in %

A Company Rebuilding From the Ground Up

To understand why Thursday’s news hit so hard, it helps to recall where Humana was twelve months ago. The stock touched a 52-week low of $163.11 on March 20, 2026 — a level that reflected deep investor skepticism about whether the company could stabilize its medical cost ratios, execute on membership growth, and restore the star ratings that underpinned its long-term earnings model. The low was not a dip — it was a crisis valuation.

The turnaround in reported numbers has been real. In Q2 2026, Humana reported revenue of $40.9 billion, up 26.2% year over year, driven primarily by Medicare membership expansion. Individual Medicare Advantage membership rose 23% while PDP membership surged 63%. Net income came in at $694 million versus $545 million in the prior-year quarter, and adjusted EPS of $7.61 beat consensus by $0.35. These are not the numbers of a company that is still in distress — they are the numbers of a company executing its recovery.

The star rating outcome now validates the revenue side of that story. Quality bonus payments will flow into 2027, supporting margins at a time when Humana needs to demonstrate to skeptics that its cost structure is sustainable, not just temporarily patched. The company has approximately 2.4 million members who will benefit from the rating improvement, according to its own disclosure. That is a meaningful portion of its total enrollment base, and the per-member economics shift materially when bonus payments kick in.

Still, anyone buying HUM at $431 is paying for perfection on a path that has had multiple stumbles. The company maintained its 2026 adjusted EPS guidance, but the specifics of 2027 margin expansion are still a model-building exercise. Optimism has a way of getting ahead of delivery in managed care.

The Numbers: Expensive for a Reason, or Just Expensive?

Thursday’s close puts Humana at a trailing P/E of 40.82 on earnings per share of $10.58. That multiple sits in a different universe from its managed-care peers. Cigna trades at a normalized P/E of roughly 8.85; CVS is around 11.22. Even on a forward basis using Cantor Fitzgerald’s upgraded 2027 EPS estimate of $17.96, Humana’s price-to-forward-earnings is approximately 24 — still a significant premium to the group.

The EV/EBITDA picture is similarly stretched. At 19.46, Humana’s enterprise value multiple sits 70% above its own 10-year median of 11.44. That gap is not inherently disqualifying — the market assigns premium multiples to companies undergoing visible earnings re-ratings — but it does raise the bar for what can go wrong. A single adverse CMS methodology change, a medical cost ratio miss, or a policy shift in Medicare Advantage funding can unwind a premium multiple faster than it builds.

The average analyst price target of $423.74, compiled across 26 analysts, is now below Thursday’s closing price. That inversion — where the stock trades above the consensus target — is usually a signal that either the street upgrades aggressively in the days ahead, or the near-term move has run past fundamental justification. This week, we got the upgrades. Whether they close the gap or the stock pulls back to meet them is the live question heading into Monday. As we covered earlier this week in our initial analysis of Humana’s gap-up, the gap structure itself carries mean-reversion risk if volume doesn’t sustain.

Data Visual

HUM Analyst Price Targets vs. October 9 Close ($431.87)

Compares key analyst price targets issued this week against Humana’s October 9 closing price, illustrating the wide dispersion in Wall Street conviction.

Values in $

Wall Street Upgrades: Conviction or Catch-Up?

Four separate analyst actions hit the tape within 48 hours of the star ratings release, spanning the full spectrum from cautious affirmation to aggressive re-rating.

The divergence between JPMorgan’s $393 neutral and Baird’s $596 bull case is a 52% spread — an unusually wide dispersion that reflects genuine uncertainty about how quickly Humana can convert a favorable regulatory ruling into realized earnings. Managed care analysts at Reuters have noted that bonus payment realization typically lags by one to two quarters as plan economics adjust, meaning 2027 EPS beats are not guaranteed to materialize on the timeline the bulls are pricing in.

The consensus rating across 23 analysts sits at buy, with 11 buy ratings, 11 holds, and 1 sell. That 11-11 buy-hold split is more cautious than the headline “consensus buy” label suggests. Half the street is watching, not buying.

Broader Tape Context: Health Care as Relative Value — or Relative Risk?

Humana’s move did not happen in isolation. The broader managed-care sector went through a significant repricing on October 9, with the star ratings release acting as a forced differentiation event — separating names that will benefit from 2027 bonus flows from those that will not. CVS and ALHC’s steep declines illustrate how zero-sum the CMS rating outcome can be across competitors.

The broader market context matters too. As we noted in our Q3 earnings season preview, equity markets are trading near highs against a backdrop of uneven economic signals. Health care names with improving earnings visibility — exactly the profile Humana now presents — tend to attract institutional rotation when macro uncertainty is elevated. That structural bid could extend HUM’s outperformance beyond the immediate catalyst window, though rising yields remain a headwind for high-multiple names across the market.

One counterpoint the bulls are not discussing loudly enough: Humana has been in this position before. The company’s star ratings history includes a severe downgrade cycle that helped drive the stock from well above $400 to below $200 within eighteen months. CMS methodology is not static, and the factors that drove the 2027 upgrade may not persist into 2028 ratings. Investors buying at current prices are making a multi-year bet on regulatory stability that the recent history of this sector does not particularly justify.

What to Watch in the Sessions Ahead

Monday’s open will tell traders more than any analyst note. If HUM gaps higher or holds above $428 — the prior 52-week high — the upgrade cycle has momentum and institutional buying is absorbing supply. If the stock fades back toward the $400–$410 range, it signals that Thursday’s move was primarily a short-squeeze and sentiment reset rather than the beginning of sustained re-rating.

Q3 2026 earnings will be the next fundamental checkpoint. Analysts will be looking for management commentary on how the star rating improvement translates into 2027 guidance language — and whether the company raises full-year 2026 adjusted EPS targets. Any hesitation on that front would pressure the stock significantly against its current valuation.

Humana has earned the right to a higher valuation after Thursday’s CMS ruling — the star rating improvement is not a rumor or a projection, it is a published federal determination. The harder question is whether the stock at $431 has already consumed two years of earnings upside in a single session. Four analyst upgrades in 48 hours is a powerful signal. So is a trailing P/E of 40 in a sector that historically trades at 10. Both things are true, and traders have until Monday’s open to decide which one matters more.